Lupin, Aurobindo Pharma Forced To Recall US Market Products

Two major pharmaceutical companies, Lupin and Aurobindo Pharma, have taken action to withdraw specific products from the US market following alerts from the US Food and Drug Administration (USFDA) regarding manufacturing issues.

According to the most recent USFDA Enforcement Report, Lupin Pharmaceuticals Inc., located in Baltimore, is recalling 3,552 bottles of Cefixime for Oral Suspension because they do not meet the required standards for uniform content. This particular batch was manufactured at their Mandideep facility in Madhya Pradesh.

In the same way, Eugia US LLC, a subsidiary of Aurobindo Pharma based in New Jersey, is recalling 70,125 vials of Dexamethasone Sodium Phosphate injection and 15,500 single-dose vials of Eptifibatide injection because they did not meet the specified standards for impurities or degradation. These recalls were initiated on May 23 and May 22 respectively.